We are live on ! Find out more
IHE icon

iShares US Pharmaceuticals ETF
IHE

139 hedge funds and large institutions have $326M invested in iShares US Pharmaceuticals ETF in 2025 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 40 increasing their positions, 39 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

2.93% more ownership

Funds ownership: 55.86% → 58.79% (+2.9%)

3% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 39

6% less capital invested

Capital invested by funds: $345M → $326M (-$19.1M)

7% less funds holding

Funds holding: 149 → 139 (-10)

42% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 24

Holders
139
Holders Change
-10
Holders Change %
-6.71%
% of All Funds
1.83%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
40
Reduced
39
Closed
24
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
+$13M
2
JP Morgan Chase
JP Morgan Chase
New York
+$6.4M
3
Goldman Sachs
Goldman Sachs
New York
+$2.19M
4
GC
Grimes & Company
Massachusetts
+$1.46M
5
Ameriprise
Ameriprise
Minnesota
+$1.28M

Top Sellers

Rank Fund Capital Flow
1
Fisher Asset Management
Fisher Asset Management
Washington
-$10.8M
2
ClearBridge Investments
ClearBridge Investments
New York
-$1.9M
3
Morgan Stanley
Morgan Stanley
New York
-$1.88M
4
Wells Fargo
Wells Fargo
California
-$1.34M
5
Bank of America
Bank of America
North Carolina
-$1.25M
Name Holding Trade Value Shares
Change 		Change in
Stake
MCM
76
Manchester Capital Management
Vermont
$197K – – –
YDMI
77
Y.D. More Investments
Israel
$177K – – –
AAS
78
Ameritas Advisory Services
Nebraska
$169K +$168K +2,574 New
BLC
79
Brown, Lisle/Cummings
Rhode Island
$156K +$8.4K +129 +6%
Comerica Bank
80
Comerica Bank
Texas
$139K -$15.5K -238 -10%
Northwestern Mutual Wealth Management
81
Northwestern Mutual Wealth Management
Wisconsin
$124K -$22.3K -343 -15%
AF
82
Allworth Financial
California
$101K +$7.03K +108 +8%
BGAI
83
Bruce G. Allen Investments
Colorado
$92K +$456 +7 +0.5%
PNC Financial Services Group
84
PNC Financial Services Group
Pennsylvania
$84K – – –
NA
85
NewEdge Advisors
Louisiana
$79.4K -$61.9K -951 -44%
Fifth Third Bancorp
86
Fifth Third Bancorp
Ohio
$76.5K -$6.12K -94 -7%
CAL
87
Capital Analysts LLC
Pennsylvania
$61K – – –
RIA
88
Realta Investment Advisors
Delaware
$59K – – –
VWM
89
Valley Wealth Managers
New Jersey
$59K – – –
MCM
90
MAI Capital Management
Ohio
$56.4K +$65 +1 +0.1%
GWM
91
Geneos Wealth Management
Colorado
$52.3K -$51.9K -798 -50%
JHCP
92
Jackson Hole Capital Partners
Oklahoma
$49.2K – – –
IA
93
IFP Advisors
Florida
$46.2K -$15.6K -240 -25%
TWC
94
TD Waterhouse Canada
Ontario, Canada
$42.7K – – –
ICM
95
Islay Capital Management
Texas
$41.3K – – –
TCOV
96
Trust Company of Vermont
Vermont
$39.9K – – –
UBP
97
Union Bancaire Privee
Switzerland
$36.9K – – –
HI
98
Harbour Investments
Wisconsin
$32.7K +$3.97K +61 +14%
PSB
99
Piscataqua Savings Bank
New Hampshire
$32.6K – – –
AT
100
Arlington Trust
Alabama
$29.5K – – –
2 3
4
5 6

IHE Hedge Fund Activity: Q2 2025 in Review

139 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q2 2025, worth a combined $326M — down 5.6% from $345M a quarter earlier.

Sellers outnumbered buyers: 24 funds closed out of IHE and 14 opened new positions — a net loss of 10 holders — while 39 trimmed existing stakes and 40 added.

The largest buyer was BNP Paribas Financial Markets, opening a new position worth an estimated $13M. The largest seller was Fisher Asset Management, cutting an estimated $10.8M.

  • 139 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q2 2025, down from 149 in Q1 2025.
  • Funds reported $326M of iShares US Pharmaceuticals ETF stock for Q2 2025, down 5.6% quarter-over-quarter.
  • 14 funds opened new iShares US Pharmaceuticals ETF positions in Q2 2025 and 24 closed out, a net change of -10 holders.
  • The largest iShares US Pharmaceuticals ETF buyer in Q2 2025 was BNP Paribas Financial Markets, an estimated $13M added.
  • The largest iShares US Pharmaceuticals ETF seller in Q2 2025 was Fisher Asset Management, an estimated $10.8M sold.

Based on aggregated 13F filings for Q2 2025.